Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 742

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 3
Chunk 742
---
SCHEDULE
OF REVENUES BY SEGMENT

    For the Years Ended 

    December 31, 

    2024  
    %  
    2023  
    % 
  
    IHEEZO 
    $49,303,000  
     25% 
    $20,621,000  
     16%
  
    VEVYE 
     28,061,000  
     14% 
     1,766,000  
     1%
  
    Other branded products 
     37,836,000  
     19% 
     15,125,000  
     12%
  
    Other revenue, net 
     915,000  
     0% 
     12,746,000  
     10%
  
    Branded revenue, net 
     116,115,000  
     58% 
     50,258,000  
     39%
  
    ImprimisRx revenue, net 
     83,499,000  
     42% 
     79,935,000  
     61%
  
    Total revenues, net 
    $199,614,000  
     100% 
    $130,193,000  
     100%

Other than IHEEZO, VEVYE, and one ImprimisRx product,
no other products accounted for more than 10% of total revenues for the periods presented.

Customer and Supplier Concentrations

Substantially all of the Company’s Branded
sales are made to third-party distributors who sell the products to pharmacies and to the end-users. There were two customers who
comprised more than 10%
of the Company’s Branded revenues for the year ended December 31, 2024 and one customer who comprised more than 10%
of the Company’s Branded revenues for the year ended December 31, 2023. There were no customers who comprised more than 10%
of ImprimisRx revenues for the years ended December 31, 2024 and 2023. As of December 31, 2024 and December 31, 2023, accounts
receivable from two customers and one customer accounted for 94%
and 80%,
respectively, of total consolidated accounts receivable.

The Company received its active pharmaceutical ingredients
from two and three main suppliers